US govt argues Gilead’s patent claims are ‘insufficient’
19-05-2020
Gilead secures new anti-cancer therapy in $4.9bn deal
02-03-2020
Gilead challenges US govt patents on HIV drug Truvada
22-08-2019
Sundry Photography / Shutterstock.com
Gilead Sciences has failed in its efforts to have US government patents covering the use of HIV drugs as pre-exposure prophylaxis (PrEP) invalidated.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Gilead Sciences, HIV, PrEP, Patent Trial and Appeal Board, PTAB, Truvada, Descovy, US Patent and Trademark Office, Bernie Sanders, Alexandria Ocasio-Cortez
